Study | Year | Onset to reperfusion time, (hours). (N/C) | Sample size (N/C) | Interventions | Followup | |
---|---|---|---|---|---|---|
Nicorandil | Control | |||||
Chen et al. [6] | 2015 | 7.1/7.0 | 52/52 | 2 mg ic or 2 mg + anisodamine 2 mg ic | No treatment or anisodamine 2 mg i.c | IH, 30d |
Chen et al. [23] | 2020 | NA | 39/39 | 0.06 mg/kg ic; 2 mg/h iv for 36 h tirofiban 10 μg/kg ic; 0.1 μg/kg·m iv for 36 h | Tirofiban 10 μg/kg ic 0.1 μg/kg·m iv for 36 h | IH, 30d |
Feng et al. [5] | 2019 | 4.7/4.8 | 90/90 | 2–6 mg ic; thrombectomy; Tirofiban 10 mg/kg ic | Saline 2–6 mL i.c.; thrombectomy; Tirofiban 10 mg/kg i.c | 1,3,6 m |
Fukuzawa et al. [9] | 2000 | 4.6/4.5 | 31/31 | 4Â mg bolus iv, 6Â mg/h iv for 24Â h | No agent | IH |
Ikeda et al. [10] | 2004 | 5.2/5.7 | 30/30 | 6Â mg/h iv for 72Â h, 2Â mg ic | Isosorbide dinitrate 6Â mg/h iv for 72Â h, 2Â mg ic | IH |
Ishii et al. [11] | 2005 | 4.8/4.5 | 185/183 | 12 mg + saline 100 ml iv isosorbide 2.5-5 mg ic | Saline 100 ml i.v.; isosorbide 2.5-5 mg i.c | 2.4y* |
Ito et al. [12] | 1999 | 4.8/5.3 | 40/41 | 4Â mg bolus iv; 6Â mg/h for 24Â h 15Â mg/day po (a mean of 28Â days) | No agent | IH |
Kitakaze et al. [13] | 2007 | 4.20/4.25 | 276/269 | 0.067 mg/kg bolus iv 1∙67 μg/kg.min iv for 24 h | Saline by the same method |  2.5y* |
Lee et al. [14] | 2008 | 5.9/5.8 | 37/36 | 2Â mg ic before CAG 2Â mg ic before stenting | No agent | IH;30d |
Miyazawa et al. [15] | 2006 | 6.1/8.0 | 35/35 | 2Â mg ic distal to lesion; 2Â mg/h for 24hiv; 15Â mg/d po | No agent | 8Â m |
Nameki et al. [16] | 2004 | 5.85/6.17 | 13/27 | 4Â mg iv 4Â mg ic before reperfusion, 4Â mg/h iv for 24Â h | Magnesium: 10Â mmol iv before reperfusion, 0.4Â mmol/h for 24Â h or no agent | IH;3Â m |
Ono et al. [17] | 2004 | 5.6/5.1 | 33/25 | 4Â mg bolus iv, 8Â mg/h iv for 24Â h after PCI | No agent | IH;6Â m |
Ota et al. [18] | 2006 | 4.05/3.86 | 63/27 | 1–2 mg ic or 1–2 mg ic + 4 mg bolus iv, 6 mg/h iv(total:96 mg) | No agent | IH |
Pi et al. [19] | 2019 | 6.51/6.86 | 95/45 | a:4Â mg ic, 4Â mg/h iv for 24Â h b:4Â mg ic,saline 4Â ml/h iv for 24Â h | Saline:8Â ml ic, 4Â ml/h iv for 24Â h | IH |
Qi et al. [20] | 2018 | 5.7/6.1 | 40/80 | 2 mg ic | Nitroprusside:200 μg ic or saline only | IH;3 m |
Wang et al. [21] | 2017 | 4.8/4.5/3.8* | 53/105 | 6 mg ic | NG 300 μg ic or no agent | IH;3 m |
Wang et al. [24] | 2020 | 5.9/5.7 | 59/60 | iv, dosage not mentioned | No agent | 6Â m |
Yamada et al. [22] | 2015 | 6.4/6.8 | 28/24 | 0.2Â mg/kg ic before the initial and final angiograms;2.0Â mg/h iv for 4Â days | Nitroglycerin 0.2Â mg/kg ic before the initial and final angiograms;2.0Â mg/h iv for 4Â days | IH |